SAN DIEGO, Nov. 20 PacificGMP, the leader in single-usebioprocessing for development and manufacturing, has entered into a cGMPcontract manufacturing agreement with Actinium Pharmaceuticals, abiopharmaceutical company developing new targeted therapies for cancer. Underthe agreement, PacificGMP will manufacture and perform fill/finish ofActinium's HuM195 monoclonal antibody for a Phase I/II clinical trial. Astability study of the final product will also be conducted. HuM195 is amonoclonal antibody that is currently being tested in a Phase I clinical trialto treat acute myeloid leukemia.
"We are delighted to establish a partnership with Actinium Pharmaceuticalsand initiate cGMP production for their new Phase I/II clinical trial," saidLeigh N. Pierce, President of PacificGMP. "With our strong track record ofmonoclonal antibody production, this project is a perfect fit for ourcompanies and we look forward to efficiently providing Actinium with a highquality GMP product."
"We are excited to work with PacificGMP, a company with demonstratedexpertise in biopharmaceutical manufacturing. Their capabilities and abilityto quickly step into this role are precisely what Actinium was looking for ina manufacturing partner," said Howard Wachtler, President and Chief ExecutiveOfficer for Actinium.
PacificGMP is a contract manufacturer and industry leader in single-usetechnology for development and manufacturing of biologics. Single-usetechnology eliminates the risk of cross-contamination, has fewer systemrequirements and significantly reduces the time required to initiateproduction. Benefits to clients include rapid project turnaround and the mostcost effective solution in the industry. PacificGMP partners with drugdevelopers by providing a range of cGMP and non-GMP services from cell lineoptimization, early process design, development and scale-up, to preclinical,clinical manufacturing, aseptic filling, testing, analytical services andregulatory support. More information can be found by visiting the Company'sweb site at www.PacificGMP.com.
About Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc. is engaged in the development andcommercialization of alpha particle immunotherapeutics based on its uniquepatent position for the utilization of actinium-225 and bismuth-213. It hasfacilities in Florham Park, New Jersey and Oak Ridge, Tennessee. Moreinformation can be found by visiting the Company's web site atwww.actiniumpharmaceuticals.comContact: PacificGMP Gary Pierce Chief Business Officer 858-550-4094Available Topic Expert(s): For information on the listed expert(s), clickappropriate link.Leigh Piercehttp://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=67271